# ACUTE STROKE AND TIA MANAGEMENT






Carlos García-Esperón John Hunter Hospital

#### Learning Objectives:

- Management of TIA/minor stroke
  - Identify red flags in Minor stroke and Transient Ischaemic Attacks (TIAs) that require urgent review reducing the subsequent risk of further stroke.
  - $\circ$  When to and who to refer to for urgent follow up and tests that need to be organised.
- Emergency Department acute stroke assessment and management.
  - How to assess Hyper-acute stroke patients
  - What is the Current Hyper-acute stroke treatment?
- □ Stroke/TIA Secondary prevention
  - What are the relevant Investigations, Medications, Follow up?
  - Hyperacute stroke
  - NSW telestroke / pre hospital phase
  - TIA / Minor stroke management




Google



# WITH A STROKE, TIME LOST IS BRAIN LOST.

Learn more at StrokeAssociation.org or 1-888-4-STROKE.







# EARLY NOTIFICATION OF STROKE TEAM!

#### Estimated Pace of Neural Circuitry Loss in Typical Large Vessel, Supratentorial Acute Ischemic Stroke

	Neurons Lost	Synapses Lost	Myelinated Fibers Lost	Accelerated Aging
Per Stroke	1.2 billion	8.3 trillion	7140 km/4470 miles	36 y
Per Hour	120 million	830 billion	714 km/447 miles	3.6 y
Per Minute	1.9 million	14 billion	12 km/7.5 miles	3.1 wk
Per Second	32 000	230 million	200 meters/218 yards	8.7 h

Saver, Stroke 2006

Total number of neurons: 85 billion

## MR X.

### 77 years old male.

Alcohol consumption: 4-5 beers per day.

Atrial fibrillation; on Dabigatran 5 years ago. Stopped. Reason?

Yesterday, at 17.00, at the pub.

Headache, word finding difficulties, right side weakness.

Called ambulance 000

Arrived hospital at 18:15


### I IN 6 AUSTRALIANS WILL SUFFER A STROKE


Stroke is one of the leading causes of disability in Australia 50,000 new strokes each year in Australia

An ischemic stroke occurs when a brain artery is occluded

If the artery remains blocked for more than a few minutes, the neurons die

The goal for both of these treatment strategies is early reperfusion (dissolving or removing the clot).





### MR X ED ARRIVALI8:35 / SO 17:00)

Left gaze preference, right homonimous hemianopia, right central facial palsy, Right hemiparesis (A1/5 - L3/5), right hypoesthesia, mixed aphasia.


NIHSS 20


ECG, Blood tests are normal

What kind of brain imaging should be ordered?

a- Brain CT b- Brain CTA c- Brain CTP d- Brain MRI e- Cerebral angiogram f- A+B+C








# MULTIMODAL IMAGE, BRAIN CT+CTA+CTP


Using the contrast injection movie, we calculate Cerebral blood flow, volume, and transit (MTT and Tmax/Delay Time)

**Core** long DT+ low CBF (no blood enters the region of the infarct)


#### Penumbra

long DT + normal or high CBF (maximal vasodilation)






#### CT PERFUSION - CORE / PENUMBRA MAPS



#### CT VS MRI IN ACUTE ISCHEMIC STROKE

# **HUMAN PENUMBRA**



#### 1980's

PET studies suggested penumbra exists in humans and even for long period

## WORLD HAS CHANGED




# WHY DO CTP BEFORE TREATMENT?

- <u>Target mismatch (core <70 mL, penumbra >15 mL)</u>
  - 23 times greater chance of excellent outcome compared to untreated
  - 77% reduction in mortality
- <u>Large core volume (>70mL)</u>
  - 48% increase of mortality and x9 symptomatic intracerebral haemorrhage
- <u>Small perfusion lesion (<15 mL)</u>
  - One-third of all lysis eligible strokes
  - No significant benefit from thrombolysis (Bivard, 2018 Annals of Neurology)
- <u>No target mismatch</u>
  - I6 times greater chance of poor clinical outcome and death if treated

### AND NOW, WHAT TO DO?

- A Start Aspirin 100mg + Clopidogrel 75mg STAT
- B Start Heparin iv.
- C Start Alteplase (rTPA)
- D Tenecteplase 0.25mg/kg
- E- Endovascular clot retrieval
- F Alteplase + Endovascular clot retrieval

## THROMBOLYSIS






Delivered at rural hospitals of the Telestroke network The majority of patients do not benefit Thrombolysis is not ideal to dissolve big clots

### LIMITATIONS

### Not for everyone

- Patients on Warfarin (if INR >1.7)
- Patients on NOAC (and compliant)
- Recent surgery (2 weeks)
- Pregnancy




# MR X AFTER TPA (18:50 - SO:17:00)

- No clinical improvement.
- Still right side weakness, mixed aphasia, and h.hemianopia.

## THROMBECTOMY / ENDOVASCULAR CLOT RETRIEVAL

For patients with ischemic stroke caused by a large artery occlusion and brain tissue to save

24 hour window





### OUTCOME OF THROMBECTOMY TRIALS (2015)

#### 3 month outcome after disabling stroke

	Thrombectomy	Medical treatment
Independent	46%	26.5%
Moderate dependent	32.5%	41.1%
Bed bound/Dead	21.5%	34.4%

## OUTCOME OF THROMBECTOMY TRIALS (2015)

#### 3 month outcome after disabling stroke

	Thrombectomy	Medical treatment
Independent	46%	26.5%
Moderate dependent	32.5%	41.1%
Bed bound/Dead	21.5%	34.4%

Number need to treat = 3

# **CIP, IMAGNG VODALITY FOR THROVEECIONY**

#### ORIGINAL ARTICLE


#### Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct

Raul G. Nogueira, M.D., Ashutosh P. Jadhav, M.D., Ph.D., Diogo C. Haussen, M.D., Alain Bonafe, M.D., Ronald F. Budzik, M.D., Parita Bhuva, M.D., Dileep R. Yavagal, M.D., Marc Ribo, M.D., Christophe Cognard, M.D., Ricardo A. Hanel, M.D., Cathy A. Sila, M.D., Ameer E. Hassan, D.O., <u>et al.</u>, for the DAWN Trial Investigators\*

#### ORIGINAL ARTICLE

#### Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging

Gregory W. Albers, M.D., Michael P. Marks, M.D., Stephanie Kemp, B.S., Soren Christensen, Ph.D., Jenny P. Tsai, M.D., Santiago Ortega-Gutierrez, M.D., Ryan A. McTaggart, M.D., Michel T. Torbey, M.D., May Kim-Tenser, M.D., Thabele Leslie-Mazwi, M.D., Amrou Sarraj, M.D., Scott E. Kasner, M.D., <u>et al.</u>, for the DEFUSE 3 Investigators<sup>\*</sup>



# **CIP, IMAGNG MODALITY FOREOR**

#### ORIGINAL ARTICLE

#### Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct

Raul G. Nogueira, M.D., Ashutosh P. Jadhav, M.D., Ph.D., Diogo C. Haussen, M.D., Alain Bonafe, M.D., Ronald F. Budzik, M.D., Parita Bhuva, M.D., Dileep R. Yavagal, M.D., Marc Ribo, M.D., Christophe Cognard, M.D., Ricardo A. Hanel, M.D., Cathy A. Sila, M.D., Ameer E. Hassan, D.O., <u>et al.</u>, for the DAWN Trial Investigators\*


#### ORIGINAL ARTICLE

#### Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging

Gregory W. Albers, M.D., Michael P. Marks, M.D., Stephanie Kemp, B.S., Soren Christensen, Ph.D., Jenny P. Tsai, M.D., Santiago Ortega-Gutierrez, M.D., Ryan A. McTaggart, M.D., Michel T. Torbey, M.D., May Kim-Tenser, M.D., Thabele Leslie-Mazwi, M.D., Amrou Sarraj, M.D., Scott E. Kasner, M.D., <u>et al.</u>, for the DEFUSE 3 Investigators<sup>\*</sup>




# MR X : SUCCESFUL THROMBECTOMY






# F UP IMAGE




### TENECTEPLASE? NOT YET


More fibrin-specific than alteplase (tPA) More resistant to plasminogen activator inhibitor-1 than tPA ½ life longer than other lytics




### Phase IIB TNK vs tPA (NEJM 2012)



#### % Reperfusion



Results	N=221 Combined therapy "Bridging"	N=217 Primary Thrombectomy EVT alone
90-day mRS 0-2	51.6% (114/221)	56.7% (123/217)
90-day mRS shift	-	-
90-day mRS 0-1	37.6% (83/221)	39.2% (85/217)
90-day mRS 0-3	67.0% (148/221)	70.0% (152/217)




Modified Rankin Scale (mRS)

# NO EVIDENCE TO SKIP TPA BEFORE THROMBECTOMY







### IMPLEMENTATION: EDUCATION AND TRAINING FOR STAFF



Prof Rohan Walker et al (UoN / HMRI)

#### **NSW Telestroke Service**



Stroke is a leading cause of long term disability and a major cause of death in NSW.

Reperfusion interventions can limit the harm caused by acute ischaemic strokes (AIS) for some patients. The sooner the intervention is made, the greater the potential to salvage brain function.

**NSW Telestroke** is a virtual care service available 24/7. It gives regional & remote hospitals access to triage tools and specialist neurology consultants who provide rapid and expert recommendations about reperfusion.

The service is being rolled out statewide to 23 regional hospitals.

Live sites


23

2333

**Telestroke cases** 

**Reperfusion recommendations** 

### NSW AMBULANCE - DIRECT NEUROLOGIST CALL




### **HUNTER-8**

Hunter 8 Item	Scoring Definition	Score on Scene	Score on Arrival
1. LOC Observations	<ul> <li>0 Alert (A)</li> <li>1 Rousable to minor stimulation (V)</li> <li>2 Rousable only to painful stimulation (P)</li> <li>3 Reflex response or unrousable (U)</li> </ul>		
<ol> <li>LOC Questions Ask patient's age and current month (must be exact)</li> </ol>	<ul><li>0 Both correct</li><li>1 One correct or dysarthria, foreign language</li><li>2 Neither correct</li></ul>		
<ol> <li>Commands – opens/close eyes, grip and release non paretic hand then other hand (1 step commands or mimic ok)</li> </ol>	<ul> <li>0 Both correct (OK if impaired by weakness)</li> <li>1 One correct</li> <li>2 Neither correct</li> </ul>		
<ol> <li>Best Gaze – test horizontal eye movements-tracking object/face</li> </ol>	<ol> <li>Normal</li> <li>Partial gaze, abnormal gaze in 1 or both eyes</li> <li>Forced eye deviation or total paresis which cannot be overcome</li> </ol>		
<ol> <li>Facial Palsy – show teeth, close eyes tight, raise eyebrows. If stuporous, check symmetry of grimace to pain</li> </ol>	<ul> <li>0 Normal</li> <li>1 Minor paralysis, flat nasolabial fold, asymmetrical smile</li> <li>2 Partial paralysis (lower face)</li> <li>3 Complete paralysis (upper &amp; lower face)</li> </ul>		
<ol> <li>Motor Arm – arms outstretched 90° sitting or 45° (supine) for 10 seconds. Encourage best effort. Score for Left and then right arm.</li> </ol>	<ul> <li>No drift for 10 seconds</li> <li>Drift but does not hit bed</li> <li>Some effort against gravity but can't sustain</li> <li>No effort against gravity</li> <li>No movement at all</li> <li>X Unable to assess due to amputation, fusion</li> <li>Explain</li></ul>	Left Right	Left Right
<ol> <li>Dysarthria – read or repeat list of words (see word list below)</li> </ol>	<ul> <li>0 Normal</li> <li>1 Mild-mod slurred speech but intelligible</li> <li>2 Unintelligible or mute</li> <li>X Intubated or mechanical barrier</li> </ul>		
<ol> <li>Extinction/Neglect – simultaneously touch patient on both hands or legs with their eyes closed.</li> <li>Show fingers in both visual fields</li> </ol>	<ul> <li>0 Normal none detected</li> <li>1 Neglect or extinction to double simultaneous stimulation in any modality (sensory, visual) OR visual/sensory loss on one side.</li> <li>2 Profound neglect in both visual and sensory modalities</li> </ul>		
Total Score		/24	/24

## H8 OF 8, THRESHOLD FOR LARGE STROKES



**Figure 2.** Distribution of patients with a large vessel occlusion and without large vessel occlusion (y-axis) per NIHSS-8 score (x-axis). Abbreviation: NIHSS-8, National Institutes of Health Stroke Scale-8.



## TIA / MINOR STROKE MANAGEMENT

"Transient episode of neurologic dysfunction caused by focal brain, spinal cord, or retinal ischemia"

AHA definition now includes **Absence of Infarct on Imaging**. Clinical definition = No residual symptoms at 24 hours.

TIA / minor stroke = spectrum of same disease

## What brain imaging to do?

Detecting acute ischemia in NCCT after symptoms that resolve within 24 hours is low (4%)

MRI (DWI) is highly sensitive (88% sensitivity) and specific (95% specificity) for acute infarction

## URGENT TREATMENT!


• Untreated: high short term risk for subsequent events (7-17% 90-day risk recurrent stroke)<sup>1</sup>.

- Treatment antithrombotic ± BP lowering, statin and assessment for AF and symptomatic carotid stenosis → may prevent ≥ 80%.
- Early antithrombotics = majority of benefit

Correct Identification is key: History (sudden onset) + Examination + Investigations

## SYMPTOMS

Major arteries serving the brain (inferior view, right side of cerebellum and part of right temporal lobe removed)



- Unilateral weakness (Face-Arm-Leg)
- Aphasia
- Hemianopia
- Unilateral numbness (Face/Arm/Leg)

- Isolated dysarthria
- Numbness I limb
- Isolated dizziness

# TIA RISK STRATIFICATION

#### All symptoms are not equal:

- Dysarthria, ataxia, confusion, vertigo 
   poor predictive value.
- Aphasia, hemiparesis 
   → much stronger predictive value.

# ABCD2 scoring system – helps stratify risk – particularly in non-specialist hands. Addition of Imaging (MRI) → better prediction.

Remains controversial – does not tell you about carotids

The ABCD <sup>2</sup> score can be used to estimate the risk of ischemic stroke in the first two days after TIA. The score is tallied as follows:			
Age:			
≥60 years	1 point		
<60 years	0 points		
Blood pressure elevation when first assessed after TIA:			
Systolic ≥140 mmHg <b>or</b> diastolic ≥90 mmHg	1 point		
Systolic <140 mmHg <b>and</b> diastolic <90 mmHg	0 points		
Clinical features:			
Unilateral weakness	2 points		
Isolated speech disturbance	1 point		
Other	0 points		
Duration of TIA symptoms:			
≥60 minutes	2 points		
10 to 59 minutes	1 point		
<10 minutes	0 points		
Diabetes:			
Present	1 point		
Absent	0 points		

# **EXCLUDING A STROKE**

## I.It is only a TIA if the patient is completely neurologically normal:

- No visual field defect.
- No sensory inattention.
- No dysarthria.
- No dysphasia (follows 3-step command, names low frequency words).

# TIA/STROKE MIMICS

• Looks like TIA / stroke, but it is something else

• 5% - 17% of total ED presentations


Common mimics
Seizures
Syncope
Functional disorders - 60%
Migraine with aura
Sepsis
Brain tumor
Metabolic
BPPV
Drugs
Bell's palsy
Transient global amnesia

## MORE LIKELY MIMIC

## **Positive symptoms**

- Indicate an excess of neuronal electrical activity
- Visual: flashing lights, zig zag shapes, lines, shapes, objects
- Motor: jerking limb movements
- Onset: Progressive

Stroke / TIA - Negative symptoms - Loss of functionality



## MECHANISMS AND TESTS

#### ATHEROSCLEROTIC

Atherosclerosis > 50% stenosis of relevant extra or intracranial artery


Most common location: Carotids

Can cause ischemic infarction due to:

• Local thrombosis / Embolism /Distal hypoperfusion

All patients with carotid territory stroke or TIA should have extracranial vessels assessed

Carotid US CT Angiography / MR Angiography



#### Carotid bifurcation on DSA



## **CAROTID STENOSIS**

#### Who to Treat? Controversy lessening

- Symptomatic vessels (recent TIA in the relevant territory) 70-99% stenosis → revascularise.
- Asymptomatic vessels not as strong benefit, but evidence growing (specially in >80%).

Not advocating screening, or carotid dopplers for everyone! Vessels on the asymptomatic side detected during stroke work up may be worth treating

#### How?

Carotid endarterectomy. Consider stenting in young (<70 y).</li>

#### When?

Within 2 weeks from event greater benefit

# TIA ANTIPLATELET THERAPY

#### **CHANCE Trial** (China) 21 days A+C:

- 5000 pts, <24h of high risk TIA or minor stroke randomised to A+C (300mg loading, then 75mg, + ASA x 21 days then Clopidogrel alone to 90 d.) or Aspirin alone
- 32% relative risk reduction (3.5% ARR) of recurrent stroke at 90 days with A+C, no difference bleeding.


#### **POINT Trial (US, Europe, Newcastle, other Aust)** 90 days A+C:

- I.5% absolute risk (30%RRR) reduction major ischemic events (most in 1<sup>st</sup> 3/52)
- 0.5% absolute risk increase of major haemorrhage (most in subsequent 9/52).

I.Wang et al. NEJM 2013 n.b. Ed. Commentary by G Hankey (Perth) 2. Johnston et al. NEJM 2018




# **Results: Major Ischemic Events**




# CARDIOEMBOLIC SOURCE

## Different vascular territories may be affected when the source is the heart Bilateral infarctions



# ECG – SHORT PERIOD

For high-risk stroke/TIA workup, not routine population screening



ECG / 24 h ECG telemetry

Kardia iECG (200 AUD)

#### Apple Watch (600 AUD)

# ECG – LONG PERIOD





## 30-day HeartBug

Loop recorder implant

# LACUNAR STROKE

Vascular risk factors leads to hyperplasia of the wall vessel: **Lypohyalonisis** 

Brainstem and basal ganglia


Always subcortical and inferior to 15 mm.

#### Secondary to vasc risk factors

- Smoking
- Sugar
- Hypertension
- Hypercholesterolemia

#### Ischaemic Cerebrovascular Accident

Left side Coronal section of brain to show the path of the Middle Cerebral Artery.



#### **Antiplatelet therapy + Statins + Risk factor control!**

#### PFO does not cause strokes

Incidental finding: 20-25% population

**But** emboli from venous circulation can by-pass lungs and cause stroke if PFO +

PFO screen indicated in young patients (<60 y old) with possible embolic (cortical) stroke/TIA and no other clear cause of the stroke/TIA.

If patient performing a Valsalva maneuver at onset might suggest PFO mechanism

**Complementary test** Bubble study request in TTE TOE Right-left shunt by transcranial doppler

# YOUNG STROKE PATIENT

Carotid / vertebral dissection




## AF AND ANTICOAGULATION

- Paroxysmal, persistent and permanent AF have increased stroke risk.
  - (approx 3x RR on average NVAF; 17x RR for AF + Valvular HD).
- Indications for DOAC CHA<sub>2</sub>DS<sub>2</sub>VASc> I or 2.
  - $CHA_2DS_2VASc 0 \rightarrow no Rx$  (ASA is not recommended NHF and other guidelines).
- N.b. Scoring irrelevant if prior event?:
  - Stroke risk in pts with prior stroke / TIA = 13.4%, v. 4.1% in those without<sup>1</sup>
- Warfarin just indicated for mechanical valves, or severe mitral stenosis with AF.

# **CRYPTOGENIC STROKE AND AF**

- 20-40% ischaemic stroke are "cryptogenic"
- Insertable loop recorder increased detection rate for AF (>30secs) in this group from 1.4% to 8.9% after 6 months (12.4% at 12 months), with treatment implications.
- Heart-bug ECG recorder (30-day)

Sanna et al. 2014. NEJM. 370:2478-86



2 large multicenter randomized clinical trials comparing antiplatelet versus DOAC in cortical strokes (NAVIGATE-ESUS and RESPECT-ESUS)

Negative for secondary prevention of ischemic events Increased haemorrhagic risk in DOAC group

Conclusion: AF needs to be captured!

## **REFERRAL PATHWAY**

- Stroke / TIA clinic (Rapid access)
- 6 sessions per week at JHH
- Referral fax: 4921 34 88 Addressed to Prof Neil Spratt, Dr Alvin Chew or myself
- Telestroke clinic MBH (please, flag that patient is from Manning area)
  - Weekly
  - Referral to local stroke coordinator MBH (Position TBA) / JHH
  - Maitland stroke clinic (please, flag that patient is from Maitland area)
  - Fortnightly (starting Feb 2022)
  - Referral to be sent to the JHH

#### If Questions?

In-hours stroke fellow at JHH (8-5pm Monday – Friday)

#### SUMMARY: TIA PATHWAY

- Exclude ICH (NCCT).
- Determine mechanism:
  - Carotid Stenosis (duplex / CTA / MRA)
  - AF? ECG +/- Holter Anticoagulate
  - <60 y.o. cryptogenic => PFO? (TTE agitated saline bubble study).

- If not in AF:
  - Clopidogrel 300 mg stat, + 75 mg daily.


+

- X 3 weeks, then single Antiplatelet and Statins
- Aspirin 300 mg stat + 100-150 mg daily.


**Referral to stroke clinic (JHH)** 

## THANKS!

**Q?** carlos.garciaesperon@health.nsw.gov.au




# PHYSIOPATHOLOGY



<u>2-4 minutes</u> after O2 and glucose deprivation







The brain receives about 20 % of the cardiac output although it is only 2 % of body weight.


The brain contains little or no energy stores of its own.

Even brief deprivation can lead to death of the affected brain tissue.









### **HUNTER-8**


### $\textbf{Hunter-8} \geq \textbf{8}$

<sup>1</sup>/<sub>2</sub> patients have a large vessel occlusion (ECR candidates) or ICH

Hunter 8 Item	Scoring Definition	Score on Scene	Score on Arriva
1. LOC Observations	<ul> <li>0 Alert (A)</li> <li>1 Rousable to minor stimulation (V)</li> <li>2 Rousable only to painful stimulation (P)</li> <li>3 Reflex response or unrousable (U)</li> </ul>		
<ol> <li>LOC Questions Ask patient's age and current month (must be exact)</li> </ol>	<ul><li>0 Both correct</li><li>1 One correct or dysarthria, foreign language</li><li>2 Neither correct</li></ul>		
<ol> <li>Commands – opens/close eyes, grip and release non paretic hand then other hand (1 step commands or mimic ok)</li> </ol>	<ul> <li>Both correct (OK if impaired by weakness)</li> <li>One correct</li> <li>Neither correct</li> </ul>		
<ol> <li>Best Gaze – test horizontal eye movements-tracking object/face</li> </ol>	<ol> <li>Normal</li> <li>Partial gaze, abnormal gaze in 1 or both eyes</li> <li>Forced eye deviation or total paresis which cannot be overcome</li> </ol>		
<ol> <li>Facial Palsy – show teeth, close eyes tight, raise eyebrows. If stuporous, check symmetry of grimace to pain</li> </ol>	<ol> <li>Normal</li> <li>Minor paralysis, flat nasolabial fold, asymmetrical smile</li> <li>Partial paralysis (lower face)</li> <li>Complete paralysis (upper &amp; lower face)</li> </ol>		
<ol> <li>Motor Arm – arms outstretched 90° sitting or 45° (supine) for 10 seconds. Encourage best effort.</li> <li>Score for Left and then right arm.</li> </ol>	<ul> <li>No drift for 10 seconds</li> <li>Drift but does not hit bed</li> <li>Some effort against gravity but can't sustain</li> <li>No effort against gravity</li> <li>No movement at all</li> <li>Unable to assess due to amputation, fusion</li> <li>Explain</li> </ul>	Left Right	Left Right
<ol> <li>Dysarthria – read or repeat list of words (see word list below)</li> </ol>	<ul> <li>0 Normal</li> <li>1 Mild-mod slurred speech but intelligible</li> <li>2 Unintelligible or mute</li> <li>X Intubated or mechanical barrier</li> </ul>		
<ol> <li>Extinction/Neglect – simultaneously touch patient on both hands or legs with their eyes closed.</li> <li>Show fingers in both visual fields</li> </ol>	<ol> <li>Normal none detected</li> <li>Neglect or extinction to double simultaneous stimulation in any modality (sensory, visual) OR visual/sensory loss on one side.</li> <li>Profound neglect in both visual and sensory modalities</li> </ol>		
Total Score		/24	/2

### ED ACUTE ASSESSMENT: WHEN TO CALL?

- Time from onset
- Severity of symptoms: NIHSS
- Pre-morbid status mRS / DBS



## STROKE TRIAGE - ROUNDS

💠 ED Triage - Hunter / New England					
Presentation					
Last seen well			Summary of events		
Choose	~]				
Premorbid Function					
Living situation	Mobility aid	used			Washing, dressing, toileting
Choose 🗸	Choose			~	Choose Y
Higher Centres					
Consciousness	Language			_	Dysarthria. If not obviously present, have patient read
Choose Y	Choose			~	Choose 🗸
Orientation & comprehension					
What age are you?	Correct	Incorrect			
What month is it?					
Close then open your eyes					
Make a fist and open it again					

## I.4 STROKE FTE...



Population 920 370

Area 131 785 km<sup>2</sup>



Population 211 000 Area 11 335 km<sup>2</sup>

## REFERRAL TO STROKE CLINIC - TIPS

### **TESTS**

-NCCT is a must

-CTA ideal (specially if PMH of AMI, PVD or crescendo TIA), otherwise carotid ultrasound (GP to organize)

-MRI – patent has to pay as outpatient.. Don't write it!

-TTE and 24 h ECG telemetry if required

- <u>Call Stroke team if doubts.</u>

- Be realistic in the message. Follow up in 2 weeks??? It takes us 4-6 weeks most of the time
- Limited capacity 7 stroke sessions / week but patients from all HNE / MNC

### Is it a stroke / TIA??

## SECONDARY PREVENTION

- Dual antiplatelet-3 weeks then monotherapy, high dose Statin
- AF Anticoagulation
- Avoid Aspirin + NOAC
- Warfarin is the past
- Don't forget the life style risk factors smoking, alcohol

### Driving

- TIA no driving 2 weeks (4 weeks for commercial licence)
- Minor stroke not for 4 weeks (3 months for commercial)

## **REFERRAL TO STROKE/TIA CLINIC**

- Urgent rapid Stroke /TIA clinic referrals to be faxed to (02) 49213488
- John Hunter Hospital neurology department
- (page 11 of ED stroke/TIA pathway)
- Non urgent -RIMS (Referral information management system)
- Fax 49236417

## THANKS!

carlos.garciaesperon@health.nsw.gov.au

### STROKE MIMICS

• Looks like stroke, but it is something else

• 5% - 17% of total ED presentations


Common mimics
Seizures
Syncope
Conversive disorders – 60%
Migraine with aura
Sepsis
Brain tumor
Metabolic
BPPV
Drugs
Bell's palsy
Transient global amnesia


#### John Hunter Emergency Acute Stroke Procedure

Pre-hospital	NSWA to notify Stroke Fellow who will d	etermine interior the patient b.	
Notification:	1) For Acute Stroke Intervention:	2) NOT for Acute Stroke Intervention:	
	Meet Stroke Doctor in the ED and continue along acute intervention pathway.	Triage assessment on arrival - if acute stroke is suspected from triage call stroke team / otherwise usual ED management.	
For all self-prese	nting stroke patients / any stroke patient not so to ED triage outlined	reened by paramedics pre-hospital proceed directly I below:	Sec.
Arrival / Triage:	Stroke triage guided by the 'Stroke Triage	e - Rounds' triage tool (found on HNE intranet)	ഉദിന്ന സ്തിനം
	All acute strokes to receive an ATS catego	ory 2 (at minimum)	0
	Determine presence of immediate life thr	• • •	5
	1) If requiring urgent resuscitation		~
	<ol><li>If medically stable continue particular</li></ol>	athway directly to CT	
IV Access:	18 gauge IVC inserted In the case of difficult access (if > 2 attem	npts or >10 minutes ) — transfer to resus	
Encilitate	Stroke Doctor to coordinate CT scan		0
Facilitate CT scan:	Nurse escort required (appropriate skill i.	e resus level)	പ്പിന്ന സ്തിനം
CT Stath.	Ideally transfer with NSWA on stretcher (	-	8
		transfer with ED nurse, medical officer and any	e
	equipment required		Ğ
			2
All hyper acute s	troke patients return to resus (or appropriate s ing CT until a decision is made on the	ubstitute with 1:1 supervision) immediately follow- e need for acute therapy	D
All hyper acute s	ing CT until a decision is made on the		
	ing CT until a decision is made on the Following review of the CT, the stroke team	e need for acute therapy	
No Acute	ing CT until a decision is made on the Following review of the CT, the stroke team	e need for acute therapy will direct care along one of the following pathways:	
No Acute	ing CT until a decision is made on the Following review of the CT, the stroke team Continue care along the stroke pathway	e need for acute therapy will direct care along one of the following pathways:	
No Acute	ing CT until a decision is made on the Following review of the CT, the stroke team Continue care along the stroke pathway Monitor in a resuscitation bed	will direct care along one of the following pathways: r in a clinically appropriate area of the department.	
No Acute	ing CT until a decision is made on the Following review of the CT, the stroke team Continue care along the stroke pathway Monitor in a resuscitation bed Establish 2nd point of IV access Ensure no contraindications as per path Administer Thrombolytic agent as direct	will direct care along one of the following pathways: r in a clinically appropriate area of the department. way (i.e. BP controlled below 185/110) ted by Stroke Doctor:	
No Acute	<ul> <li>ing CT until a decision is made on the</li> <li>Following review of the CT, the stroke team</li> <li>Continue care along the stroke pathway</li> <li>Monitor in a resuscitation bed</li> <li>Establish 2nd point of IV access</li> <li>Ensure no contraindications as per path</li> <li>Administer Thrombolytic agent as direct</li> <li>Alteplase: Confirm dose, do not shadow</li> </ul>	will direct care along one of the following pathways: rin a clinically appropriate area of the department. way (i.e. BP controlled below 185/110) ted by Stroke Doctor: ake vial while reconstituting, administer bolus dose	
No Acute Therapy	<ul> <li>ing CT until a decision is made on the</li> <li>Following review of the CT, the stroke team</li> <li>Continue care along the stroke pathway</li> <li>Monitor in a resuscitation bed</li> <li>Establish 2nd point of IV access</li> <li>Ensure no contraindications as per path</li> <li>Administer Thrombolytic agent as direct</li> <li>Alteplase: Confirm dose, do not shat as an IV push immediately followed</li> </ul>	will direct care along one of the following pathways: in a clinically appropriate area of the department. way (i.e. BP controlled below 185/110) ted by Stroke Doctor: ake vial while reconstituting, administer bolus dose by the infusion (delivered by syringe driver).	
No Acute	<ul> <li>ing CT until a decision is made on the</li> <li>Following review of the CT, the stroke team</li> <li>Continue care along the stroke pathway</li> <li>Monitor in a resuscitation bed</li> <li>Establish 2nd point of IV access</li> <li>Ensure no contraindications as per path</li> <li>Administer Thrombolytic agent as direct</li> <li>Alteplase: Confirm dose, do not sha as an IV push immediately followed</li> <li>Tenecteplase (acute stroke research</li> </ul>	will direct care along one of the following pathways: in a clinically appropriate area of the department. way (i.e. BP controlled below 185/110) ted by Stroke Doctor: ake vial while reconstituting, administer bolus dose by the infusion (delivered by syringe driver). h trial patients only): Confirm dose (stroke dose of	
No Acute Therapy	<ul> <li>ing CT until a decision is made on the</li> <li>Following review of the CT, the stroke team</li> <li>Continue care along the stroke pathway</li> <li>Monitor in a resuscitation bed</li> <li>Establish 2nd point of IV access</li> <li>Ensure no contraindications as per path</li> <li>Administer Thrombolytic agent as direct</li> <li>Alteplase: Confirm dose, do not shat as an IV push immediately followed</li> <li>Tenecteplase (acute stroke research 0.25mg/kg is different to cardiac do</li> </ul>	will direct care along one of the following pathways: in a clinically appropriate area of the department. way (i.e. BP controlled below 185/110) ted by Stroke Doctor: ake vial while reconstituting, administer bolus dose by the infusion (delivered by syringe driver).	
No Acute Therapy	<ul> <li>ing CT until a decision is made on the</li> <li>Following review of the CT, the stroke team</li> <li>Continue care along the stroke pathway</li> <li>Monitor in a resuscitation bed</li> <li>Establish 2nd point of IV access</li> <li>Ensure no contraindications as per path</li> <li>Administer Thrombolytic agent as direct</li> <li>Alteplase: Confirm dose, do not sha as an IV push immediately followed</li> <li>Tenecteplase (acute stroke researct 0.25mg/kg is different to cardiac do an IV push.</li> </ul>	will direct care along one of the following pathways: in a clinically appropriate area of the department. way (i.e. BP controlled below 185/110) ted by Stroke Doctor: ake vial while reconstituting, administer bolus dose by the infusion (delivered by syringe driver). h trial patients only): Confirm dose (stroke dose of	
No Acute Therapy	<ul> <li>ing CT until a decision is made on the</li> <li>Following review of the CT, the stroke team</li> <li>Continue care along the stroke pathway</li> <li>Monitor in a resuscitation bed</li> <li>Establish 2nd point of IV access</li> <li>Ensure no contraindications as per path</li> <li>Administer Thrombolytic agent as direct</li> <li>Alteplase: Confirm dose, do not sha as an IV push immediately followed</li> <li>Tenecteplase (acute stroke researct 0.25mg/kg is different to cardiac do an IV push.</li> </ul>	will direct care along one of the following pathways: in a clinically appropriate area of the department. way (i.e. BP controlled below 185/110) ted by Stroke Doctor: ake vial while reconstituting, administer bolus dose by the infusion (delivered by syringe driver). h trial patients only): Confirm dose (stroke dose of ise), reconstitute medication, deliver bolus dose as	260 mine
No Acute Therapy	<ul> <li>ing CT until a decision is made on the</li> <li>Following review of the CT, the stroke team</li> <li>Continue care along the stroke pathway</li> <li>Monitor in a resuscitation bed</li> <li>Establish 2nd point of IV access</li> <li>Ensure no contraindications as per path</li> <li>Administer Thrombolytic agent as direct</li> <li>Alteplase: Confirm dose, do not sha as an IV push immediately followed</li> <li>Tenecteplase (acute stroke researce 0.25mg/kg is different to cardiac do an IV push.</li> <li>Contact G2 in charge to inform them of unit bed as usual.</li> </ul>	will direct care along one of the following pathways: in a clinically appropriate area of the department. way (i.e. BP controlled below 185/110) ted by Stroke Doctor: ake vial while reconstituting, administer bolus dose by the infusion (delivered by syringe driver). h trial patients only): Confirm dose (stroke dose of ise), reconstitute medication, deliver bolus dose as	
No Acute Therapy	<ul> <li>ing CT until a decision is made on the</li> <li>Following review of the CT, the stroke team</li> <li>Continue care along the stroke pathway</li> <li>Monitor in a resuscitation bed</li> <li>Establish 2nd point of IV access</li> <li>Ensure no contraindications as per path</li> <li>Administer Thrombolytic agent as direct</li> <li>Alteplase: Confirm dose, do not sha as an IV push immediately followed</li> <li>Tenecteplase (acute stroke researce 0.25mg/kg is different to cardiac do an IV push.</li> <li>Contact G2 in charge to inform them of unit bed as usual.</li> </ul>	will direct care along one of the following pathways: in a clinically appropriate area of the department. way (i.e. BP controlled below 185/110) ted by Stroke Doctor: ake vial while reconstituting, administer bolus dose by the infusion (delivered by syringe driver). h trial patients only): Confirm dose (stroke dose of ise), reconstitute medication, deliver bolus dose as thrombolysis taking place - Book an acute stroke	
No Acute Therapy	<ul> <li>ing CT until a decision is made on the</li> <li>Following review of the CT, the stroke team</li> <li>Continue care along the stroke pathway</li> <li>Monitor in a resuscitation bed</li> <li>Establish 2nd point of IV access</li> <li>Ensure no contraindications as per path</li> <li>Administer Thrombolytic agent as direct</li> <li>Alteplase: Confirm dose, do not sha as an IV push immediately followed</li> <li>Tenecteplase (acute stroke researct 0.25mg/kg is different to cardiac do an IV push.</li> <li>Contact G2 in charge to inform them of unit bed as usual.</li> <li>Continue to monitor as per Stroke pathway</li> </ul>	will direct care along one of the following pathways: in a clinically appropriate area of the department. way (i.e. BP controlled below 185/110) ted by Stroke Doctor: ake vial while reconstituting, administer bolus dose by the infusion (delivered by syringe driver). h trial patients only): Confirm dose (stroke dose of ise), reconstitute medication, deliver bolus dose as thrombolysis taking place - Book an acute stroke	
No Acute Therapy	<ul> <li>ing CT until a decision is made on the</li> <li>Following review of the CT, the stroke team</li> <li>Continue care along the stroke pathway</li> <li>Monitor in a resuscitation bed</li> <li>Establish 2nd point of IV access</li> <li>Ensure no contraindications as per path</li> <li>Administer Thrombolytic agent as direct</li> <li>Alteplase: Confirm dose, do not shia as an IV push immediately followed</li> <li>Tenecteplase (acute stroke research 0.25mg/kg is different to cardiac do an IV push.</li> <li>Contact G2 in charge to inform them of unit bed as usual.</li> <li>Continue to monitor as per Stroke pathwaleast 2 hours post administration)</li> </ul>	will direct care along one of the following pathways: in a clinically appropriate area of the department. way (i.e. BP controlled below 185/110) ted by Stroke Doctor: ake vial while reconstituting, administer bolus dose by the infusion (delivered by syringe driver). h trial patients only): Confirm dose (stroke dose of ise), reconstitute medication, deliver bolus dose as thrombolysis taking place - Book an acute stroke	
No Acute Therapy	<ul> <li>ing CT until a decision is made on the</li> <li>Following review of the CT, the stroke team</li> <li>Continue care along the stroke pathway</li> <li>Monitor in a resuscitation bed</li> <li>Establish 2nd point of IV access</li> <li>Ensure no contraindications as per path</li> <li>Administer Thrombolytic agent as direct</li> <li>Alteplase: Confirm dose, do not sha as an IV push immediately followed</li> <li>Tenecteplase (acute stroke researct 0.25mg/kg is different to cardiac do an IV push.</li> <li>Contact G2 in charge to inform them of unit bed as usual.</li> <li>Continue to monitor as per Stroke pathwaleast 2 hours post administration)</li> <li>Establish 2nd point of IV access</li> </ul>	will direct care along one of the following pathways: in a clinically appropriate area of the department. way (i.e. BP controlled below 185/110) ted by Stroke Doctor: ake vial while reconstituting, administer bolus dose by the infusion (delivered by syringe driver). h trial patients only): Confirm dose (stroke dose of ise), reconstitute medication, deliver bolus dose as thrombolysis taking place - Book an acute stroke	
No Acute Therapy Thrombolysis	<ul> <li>ing CT until a decision is made on the</li> <li>Following review of the CT, the stroke team</li> <li>Continue care along the stroke pathway</li> <li>Monitor in a resuscitation bed</li> <li>Establish 2nd point of IV access</li> <li>Ensure no contraindications as per path</li> <li>Administer Thrombolytic agent as direct</li> <li>Alteplase: Confirm dose, do not shia as an IV push immediately followed</li> <li>Tenecteplase (acute stroke researct 0.25mg/kg is different to cardiac do an IV push.</li> <li>Contact G2 in charge to inform them of unit bed as usual.</li> <li>Continue to monitor as per Stroke pathwaleast 2 hours post administration)</li> <li>Establish 2nd point of IV access</li> <li>Change to gown and shave bilateral groin</li> </ul>	will direct care along one of the following pathways: in a clinically appropriate area of the department. way (i.e. BP controlled below 185/110) ted by Stroke Doctor: ake vial while reconstituting, administer bolus dose by the infusion (delivered by syringe driver). h trial patients only): Confirm dose (stroke dose of ise), reconstitute medication, deliver bolus dose as thrombolysis taking place - Book an acute stroke	
No Acute Therapy	<ul> <li>ing CT until a decision is made on the</li> <li>Following review of the CT, the stroke team</li> <li>Continue care along the stroke pathway</li> <li>Monitor in a resuscitation bed</li> <li>Establish 2nd point of IV access</li> <li>Ensure no contraindications as per path</li> <li>Administer Thrombolytic agent as direct</li> <li>Alteplase: Confirm dose, do not sha as an IV push immediately followed</li> <li>Tenecteplase (acute stroke researct 0.25mg/kg is different to cardiac do an IV push.</li> <li>Contact G2 in charge to inform them of unit bed as usual.</li> <li>Continue to monitor as per Stroke pathwaleast 2 hours post administration)</li> <li>Establish 2nd point of IV access</li> <li>Change to gown and shave bilateral groin</li> <li>Complete pre-op checklist</li> <li>Insert urinary catheter (IDC) - desirable</li> </ul>	will direct care along one of the following pathways: in a clinically appropriate area of the department. way (i.e. BP controlled below 185/110) ted by Stroke Doctor: ake vial while reconstituting, administer bolus dose by the infusion (delivered by syringe driver). h trial patients only): Confirm dose (stroke dose of ise), reconstitute medication, deliver bolus dose as thrombolysis taking place - Book an acute stroke	

## WHY PRE HOSPITAL SCALES?

"The right patient to the right hospital"





### UNEXPLAINED LOC

44 years old female


PMH / Anxiety on SSRI


Unwell + vomiting + collapse – hit head on bathroom floor

Arrival JHH (60-90 minutes since onset) Extensor (decerebrate) posture, GCS 5 – Intubation

<u>Bloods</u>: Normal

37.2 C






### Differential diagnosis

Meningoencephalitis / seizure / drugs?

Admission in ICU

LP: Normal

Successful extubation day after, but need to re-intubation later that day






### Patient extubated 4 days since onset.

Locked-in syndrome.

Communicate with family blinking.



### **Prevalence** 3-5% of ischemic strokes

### Outcome with no treatment 70-90% mortality

### **SYMPTOMS**

Motor deficits (hemi or tetraparesis) - 40-65% cases

Dysarthria (+++) - 30-60%


Vertigo, nausea, and vomiting - 55-70%

Visual disturbances (diplopia, hemianopia..) - 20-30%

Altered consciousness - 20-30%

# Commenced in November 2018 at MBH

- Weekly, using current resources.
- Hybrid model
- > 280 patients assessed



## 136 (78.6%) first appointments (125 attended) 37 (21.4%) follow-up 14 (8%) of the patients failed to attend

Of the 125 first appointments

106 (84.8%): stroke or TIA by the stroke neurologist (80 ischemic strokes, 22 TIA and 4 haemorrhagic strokes).

A change in diagnosis was made by the stroke neurologist in 23 (18.4%) of the initial appointments

## MBH TELE CLINIC – INTERVENTIONS

Any intervention was made by the neurologist for 102 (81.6%) of the 125 first appointments.


Medication changed for 67 (53.6%) patients

Additional investigations requested in 72 patients (57.6%)

Referral for a stroke clinical trial on 15 patients (12%)

**Another** type of intervention: 23 patients (18.4%) *Referral to another specialist, referral for a formal driving assessment...* 

### • CT Perfusion at spoke sites



CNS Neuroscience & Therapeutics

Implementation of multimodal computed tomography in a telestroke network: Five-year experience

Carlos Garcia-Esperon<sup>1,2</sup> Frode Soderhjelm Dinkelspiel<sup>3</sup> Ferdi Miteff<sup>1,2</sup> Shyam Gangadharan<sup>1,2</sup> Tom Wellings<sup>1,2</sup> Bill O'Brien<sup>4</sup> James Evans<sup>4</sup> Tom Lillicrap<sup>1,2</sup> Jelle Demeestere<sup>5</sup> Andrew Bivard<sup>6</sup> Mark Parsons<sup>2,6</sup> Chris Levi Neil James Spratt<sup>1,2</sup> for the Northern NSW Telestroke investigators

PATIENT SEL Implementation of multimodal computed tomography in a telestroke network: Five-year experience


### N= 240

### Baseline median NIHSS: 4 [2-9]


Baseline mRS 0-2:92%


Visible vessel occlusion: 35%

Large vessel occlusion: 18%



sICH 1.7 % - Currently 0.8%





### sICH 1.7 % - Currently 0.8%

- Same core / penumbra thresholds than used at hub site?
  - Yes, but need of careful interpretation of CTP Not just core/penumbra volumes
  - Hypoperfusion Intensity Ratio<sup>1,2</sup> (Tmax>10/Tmax>6) or DT-based ratio<sup>3</sup>, useful for tissue survival
- *Repeat imaging at arrival?* 
  - Average transfer takes 4-6 hours
  - Not routinely Unless unexpected delays or clinical deterioration/improvement
  - Our single centre experience (unpublished) suggests safety / low futile thrombectomy rate

- Who should be transported?
  - EVT candidates
  - Haemorrhages
  - At risk of malignant MCA
  - Endarterectomy

<sup>1</sup> Olivot et al, Stroke (2014)
<sup>2</sup> Guenego et al, Annals of Neurology (2018)
<sup>3</sup> Lin et al, Stroke (2020)

# TRANSPORT MODALITY

• *Expensive* (In Australia paid by government)

- Understand the resources
  - Limited transport availability, high demand

- The in-theory fastest is not the real-life fastest
  - Helicopter would require round trip (sometimes not possible on a single tank of gas)
  - Lack of helipad in all the rural sites at hospital, need to transport to the airport.
  - Know the area. Know the resources

## TRANSPORT MODA Air vs. Road Decision for Frontiers Endovascular Clot Retrieval in a Rural Telestroke Network

Shyam Gangadharan<sup>1\*</sup>, Thomas Lillicrap<sup>2</sup>, Ferdinand Miteff<sup>1,2</sup>, Pablo Garcia-Bermejo<sup>1</sup>, Thomas Wellings<sup>1</sup>, Billy O'Brien<sup>3</sup>, James Evans<sup>3</sup>, Khaled Alanati<sup>1</sup>, Christopher Levi<sup>1,2</sup>, Mark W. Parsons<sup>2,4</sup>, Andrew Bivard<sup>2,4</sup>, Carlos Garcia-Esperon<sup>1,2†</sup> and Neil J. Spratt<sup>1,2†</sup> for the Northern NSW Telestroke Investigators

62 patients (20 road transfers / 42 air transfers)

Median spoke-door-to-hub-door was 308min - 68% spent at rural (DIDO 214min - IQR, 171–247]

DIDO was longer for air transfers than road (p = 0.004), median 87min greater decision-to-departure

The distance at which the extra speed of an aircraft made up for the delays involved in booking an aircraft was 299 km (185 miles) from the comprehensive stroke centre.

# FORGOTTEN FACTORS

- Emotional impact on family
  - Some families unable to visit their relatives during admission (socio-economic factors)
  - 20% mortality in LVO

- Staff and patient safety
  - Lights and sirens?

- Spoke sites / Ambulance services
  - Understand their resources
  - Provide feedback to the team
  - Know them and get them to know you
- Weather





76-year-old man

Medical history/ Heart failure AF on DOAC

Collapsed in Darwin at 5 am Initial assessment: Dysarthria and right-side ataxia.

Fluctuation of symptoms.



Slide courtesy of: Kleinig TJ, Cervera A, Scroop R

76-year-old man


Medical history/ Heart failure AF on DOAC

Collapsed in Darwin at 5 am Initial assessment: Dysarthria and right-side ataxia.

Fluctuation of symptoms.

CTA – Top of basilar occlusion

Slide courtesy of: Kleinig TJ, Cervera A, Scroop R



76-year-old man

Medical history/ Heart failure AF on DOAC


Collapsed in Darwin at 5 am Initial assessment: Dysarthria and right-side ataxia.

Fluctuation of symptoms.

CTA – Top of basilar occlusion

Contact Royal Adelaide Hospital (3000km) Patient transferred via aeromedical jet retrieval.

Slide courtesy of: Kleinig TJ, Cervera A , Scroop R



### In Adelaide


Initial examination (23:30 - 18.5 h from onset): Right facial droop and mild gait unsteadiness

CTA: persistent distal basilar occlusion Post-CTA (00:15), worsening of dysarthria and right hemiparesis

EVT: Full reperfusion at 01:05 (23 h from onset)

Day after: NIHSS 0.

Slide courtesy of: Kleinig TJ, Cervera A, Scroop R



# CONCLUSIONS

• Spend time in rural sites, know the ED and retrieval teams

Multimodal CT and imaging access is crucial in patient selection

• Use your imagination, each geographical area is different = different needs

- Extended time-window (CTP guided) = theoretical access to thrombectomy to almost everyone in the world.
  - Almost everyone is 8 h flight from a thrombectomy centre!

### PFO does not cause strokes

Incidental finding: 20-25% population

**But** emboli from venous circulation can by-pass lungs and cause stroke if PFO +

PFO screen indicated in young patients (<60 y old) with possible embolic (cortical) stroke/TIA and no other clear cause of the stroke/TIA.

If patient performing a Valsalva maneuver at onset might suggest PFO mechanism

**Complementary test** Bubble study request in TTE TOE Right-left shunt by transcranial doppler

# WHAT IS NEW


• tPA pre LVO , needed.

# WE KNOW



# STENT RETRIEVERS / ASPIRATION






Solitaire Trevo


# STENT RETRIEVERS / ASPIRATION





## TIME WINDOW





# **CTP, IMAGING MODALITY FOR THROMBECTOMY**

# AUSTRALASIAN STROKE ACADEMY

#### ORIGINAL ARTICLE


# Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct

Raul G. Nogueira, M.D., Ashutosh P. Jadhav, M.D., Ph.D., Diogo C. Haussen, M.D., Alain Bonafe, M.D., Ronald F. Budzik, M.D., Parita Bhuva, M.D., Dileep R. Yavagal, M.D., Marc Ribo, M.D., Christophe Cognard, M.D., Ricardo A. Hanel, M.D., Cathy A. Sila, M.D., Ameer E. Hassan, D.O., <u>et al.</u>, for the DAWN Trial Investigators<sup>\*</sup>

#### ORIGINAL ARTICLE

### Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging

Gregory W. Albers, M.D., Michael P. Marks, M.D., Stephanie Kemp, B.S., Soren Christensen, Ph.D., Jenny P. Tsai, M.D., Santiago Ortega-Gutierrez, M.D., Ryan A. McTaggart, M.D., Michel T. Torbey, M.D., May Kim-Tenser, M.D., Thabele Leslie-Mazwi, M.D., Amrou Sarraj, M.D., Scott E. Kasner, M.D., <u>et al.</u>, for the DEFUSE 3 Investigators<sup>\*</sup>



# **CTP, IMAGING MODALITY FOR ECR**



#### ORIGINAL ARTICLE


#### Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct

Raul G. Nogueira, M.D., Ashutosh P. Jadhav, M.D., Ph.D., Diogo C. Haussen, M.D., Alain Bonafe, M.D., Ronald F. Budzik, M.D., Parita Bhuva, M.D., Dileep R. Yavagal, M.D., Marc Ribo, M.D., Christophe Cognard, M.D., Ricardo A. Hanel, M.D., Cathy A. Sila, M.D., Ameer E. Hassan, D.O., <u>et al.</u>, for the DAWN Trial Investigators\*

#### ORIGINAL ARTICLE


### Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging

Gregory W. Albers, M.D., Michael P. Marks, M.D., Stephanie Kemp, B.S., Soren Christensen, Ph.D., Jenny P. Tsai, M.D., Santiago Ortega-Gutierrez, M.D., Ryan A. McTaggart, M.D., Michel T. Torbey, M.D., May Kim-Tenser, M.D., Thabele Leslie-Mazwi, M.D., Amrou Sarraj, M.D., Scott E. Kasner, M.D., <u>et al.</u>, for the DEFUSE 3 Investigators\*



### CT PERFUSION - CORE / PENUMBRA MAPS





## WORLD HAS CHANGED





EMBOLIC STROKE OF UNDETERMI NED SOURCE TRIALS

# RE-SPECT ESUS

enrolment completed in December 2017 after randomization of 5,390 patients

#### dabigatran 150 mg twice daily

1 randomization, double-blinded

#### aspirin 100 mg once daily

primary endpoint: time to first recurrent stroke (ischemic, hemorrhagic, or unspecified)

# NAVIGATE ESUS

terminated in October 2017 due to futility for the primary endpoint after enrolment of 7,214 patients

#### rivaroxaban 15 mg once daily

I randomization, double-blinded

#### aspirin 100 mg once daily

primary endpoint: time to first recurrent stroke (ischemic, hemorrhagic, or unspecified), magnetic resonance imaging-positive transient ischemic attack, or systemic embolism

# ATTICUS

active, up to 600 patients with embolic stroke of undetermined source and additional risk factors for subclinical atrial fibrillation; continuous or daily ECG monitoring

#### apixaban 5 mg twice daily

1:1 randomization, open-label

#### aspirin 100 mg once daily

primary endpoint: new ischemic lesions on magnetic resonance imaging after 12 months

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

## Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source

N Engl J Med 2018;378:2191-201. DOI: 10.1056/NEJMoa1802686

